Unitaid’s role in scaling up programmatic management of LTBI

1st September 2017
Maximize the effectiveness of the global health response by catalysing equitable access to better health products
Unitaid has a role to play at 3 critical moments

- **Moment 1**: Product is available
- **Moment 2**: Product is adopted
- **Moment 3**: Product is scaled-up

**Objectives**

- **Innovation**
- **Access**
- **Scalability**

Maximize the effectiveness of the global health response... 
... by catalyzing equitable access... 
... to better health products
Our mission relies on three strategic objectives

Maximize the effectiveness of the global health response by catalyzing equitable access to better health products

- **Innovation**: Linking pipelines to frontlines
- **Access**: Overcoming market barriers
- **Scalability**: Creating conditions for scale-up
Dimensions of Market Health

- Innovation & availability
- Affordability
- Quality
- Demand/ adoption
- Supply & delivery
### Unitaid’s investment in TB since 2006

<table>
<thead>
<tr>
<th></th>
<th>Tuberculosis Portfolio</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test</strong></td>
<td>US$ 116m</td>
<td>US$ 425m</td>
</tr>
<tr>
<td></td>
<td>• Introduce innovative TB diagnostic tools</td>
<td></td>
</tr>
<tr>
<td><strong>Treat</strong></td>
<td>US$ 215m + US$ ~38m in development</td>
<td>US$ &gt;1bn</td>
</tr>
<tr>
<td></td>
<td>• Create a market &amp; develop novel formulations for children;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increase access and provide uninterrupted access to quality MDR-TB medicines including novel medicines and regimens</td>
<td></td>
</tr>
<tr>
<td><strong>Prevent</strong></td>
<td>US$ ~59m</td>
<td>US$ 260m</td>
</tr>
<tr>
<td></td>
<td>• Catalysing access to shorter TB preventive therapy for high risk groups</td>
<td></td>
</tr>
</tbody>
</table>
Process

Mar 2016
• Enabling preventive TB treatment in high risk populations

May 2016
• Call for proposals launched

Dec 2016
• IMPAACT4TB proposal given go ahead for grant development

Aug 2017
• IMPAACT4TB grant submitted for approval
Unitaid’s role in enabling preventive TB treatment in high risk populations

**Challenges**

- Long (6-36 months) and complex treatment options
- Poor adherence
- Re-infection in high burden settings
- Challenging to scale up
- Information on durability
- More amenable to scale
- Formulation
- Affordability
- Models / pilots to inform and enable scale-up
Demand creation to shape the market for innovative treatments
INH is cheap and effective, yet uptake of IPT for PLHIV has been low

SOURCE: 1. IPT uptake data is from the WHO TB Report, 2. PLHIV data is from UNAIDS aidsinfo.com for all countries
Next Steps

Product development
• Safety & PK
• Affordable formulation
• Quality assured supply of API

Product Delivery
• Effective and efficient methods to reach those infected

Scale-up
• New WHO Guidelines
• Test, treat & prevent priority in TB
• LTBI testing / empirical treatment in resource-limited-HBC

Gaps left
• Testing technologies & algorithms
• DR-TB prevention
Thank you